SrihariGopalMD

PubMed

• Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of p...
  Ute Richarz, John Han, Ya-Mei Bai, Eric Yu-Hai Chen, Young Chul Chung, Venu Gopal Jhanwar, Sung-Wan Kim, Ahmad Hatim Sulaiman, Karl Knight, Srihari Gopal> ;Medicine. 2023 Aug 25
• 5 citations
  The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia.
  Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal, John M Kane> ;Neuropsychiatric Disease and Treatment. 2023 Jan 1
• Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc ...
  Cesar Giron-Hernandez, Joong Hee Han, Roberta Alberio, Arun Singh, Maria Paz García-Portilla, Maurizio Pompili, R Karl Knight, Ute Richarz, Srihari Gopal, José Antunes> ;Neuropsychiatric Disease and Treatment. 2023 Jan 1
• 9 citations
  Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health ...
  Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Camille Orman, Kruti Joshi, Arun Singh, A. Godet, Katalin Pungor, Srihari Gopal> ;Patient Preference and Adherence. 2021 Oct 2
• 3 citations
  Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Pa...
  Amy O'Donnell, Sanjai Rao, Ibrahim Turkoz, Srihari Gopal, Edward Kim> ;Neuropsychiatric Disease and Treatment. 2021 Jan 6
• 59 citations
  Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
  Christoph U. Correll, Edward Kim, Jennifer Kern Sliwa, Wayne Hamm, Srihari Gopal, Maju Mathews, Raja Venkatasubramanian, Stephen R. Saklad> ;CNS Drugs. 2021 Jan 1
• 5 citations
  Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
  Martin Lambert, Pedro M. Sanchez, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor> ;Neuropsychiatric Disease and Treatment. 2020 Dec 23
• 2 citations
  Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
  Srihari Gopal, Jagadish Gogate, Katalin Pungor, Edward Kim, Arun Singh, Maju Mathews> ;Neuropsychiatric Disease and Treatment. 2020 Mar 6
• 5 citations
  Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
  Hiroko Shimizu, Martine Neyens, Marc De Meulder, Srihari Gopal, Yuko Tsukamoto, Mahesh N. Samtani, Bart Remmerie> ;Clinical Pharmacology in Drug Development. 2020 Feb 1
• 5 citations
  Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 ran...
  Adam Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews, Bernardo Soares> ;Revista Brasileira De Psiquiatria. 2019 Apr 15
• 3 citations
  Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
  Adam Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn, David Hough, Ludger Hargarter> ;Neuropsychiatric Disease and Treatment. 2019 Feb 21
• 4 citations
  Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
  Maju Mathews, Isaac Nuamah, Adam Savitz, David Hough, Dean Najarian, Edward Kim, Srihari Gopal> ;Neuropsychiatric Disease and Treatment. 2018 Oct 25
• 9 citations
  An assessment of injection site reaction and injection site pain of 1‐month and 3‐month long‐acting injectable formulations of paliperidone palmitate
  Jennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, Maju Mathews, Srihari Gopal, Erica Elefant, Dean Najarian, Larry Alphs> ;Perspectives in Psychiatric Care. 2018 Feb 14
• 6 citations
  Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post ...
  Maju Mathews, Huiling Pei, Adam Savitz, Isaac Nuamah, David Hough, Larry Alphs, Srihari Gopal> ;Clinical Drug Investigation. 2018 Aug 1
• 21 citations
  Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse.
  Dai Wang, Srihari Gopal, Susan Baker, Vaibhav A. Narayan> ;NPJ Schizophrenia. 2018 Jun 20
• 20 citations
  Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled S...
  Robin Emsley, Isaac Nuamah, Srihari Gopal, David Hough, W. Wolfgang Fleischhacker> ;The Journal of Clinical Psychiatry. 2018 Jun 19
• 11 citations
  Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations.
  Alberto Russu, Jennifer Kern Sliwa, Paulien Ravenstijn, Arun Singh, Maju Mathews, Edward Kim, Srihari Gopal> ;International Journal of Clinical Practice. 2018 Jun 1
• 10 citations
  Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-bl...
  Adam Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn, David M Hough, Maju Mathews, Yu Feng, Lu Yu, Masayoshi Takahashi, Dennis Liu, Gang Wang, Jin-S...> ;Neuropsychiatric Disease and Treatment. 2017 Aug 17
• 11 citations
  Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy
  Mahesh N. Samtani, Partha Nandy, Paulien Ravenstijn, Bart Remmerie, An Vermeulen, Alberto Russu, Peter D'hoore, Ellen Z. Baum, Adam Savitz, Srihari Gopal, David Hough> ;British Journal of Clinical Pharmacology. 2016 Nov 1
• 19 citations
  Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.
  Eva G. Katz, Brett Hauber, Srihari Gopal, Angie Fairchild, Amy Pugh, Rachel B. Weinstein, Bennett Levitan> ;Patient Preference and Adherence. 2016 Oct 21
• 29 citations
  Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy
  Larry Alphs, Henry A. Nasrallah, Cynthia A. Bossie, Dong-Jing Fu, Srihari Gopal, David Hough, Ibrahim Turkoz> ;International Clinical Psychopharmacology. 2016 Jul 1
• 55 citations
  Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label...
  Paulien Ravenstijn, Bart Remmerie, Adam Savitz, Mahesh N. Samtani, Isaac Nuamah, Cheng‐Tao Chang, Marc De Meulder, David Hough, Srihari Gopal> ;Journal of Clinical Pharmacology. 2016 Mar 1
• 2 citations
  Safety and Efficacy of Paliperidone Extended-Release in Chinese Patients With Schizophrenia: A 24-week, Open-Label Extension of a Randomized, Double-Blind, Placebo-Con...
  Hong Yan Zhang, Huafang Li, Yanning Liu, Cathy Wu, Qingqi Wu, Isaac Nuamah, Jianguo Shi, Shiping Xie, Gang Wang, Srihari Gopal> ;Neuropsychiatric Disease and Treatment. 2016 Jan 8
• 30 citations
  Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
  Srihari Gopal, An Vermeulen, Partha Nandy, Paulien Ravenstijn, Isaac Nuamah, José Antonio Buron Vidal, Joris Berwaerts, Adam Savitz, David Hough, Mahesh N. Samtani> ;Current Medical Research and Opinion. 2015 Oct 2
• 146 citations
  Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial
  Joris Berwaerts, Yanning Liu, Srihari Gopal, Isaac Nuamah, Haiyan Xu, Adam Savitz, Danielle Coppola, Alain Schotte, Bart Remmerie, N. O. Maruta, David Hough> ;JAMA Psychiatry. 2015 Aug 1
• Join now to see all

Journal Articles

• Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence:  
  Srihari Gopal, MD, The Journal of Clinical Psychiatry